1. HOME
  2. WORKS
  3. FUNCTIONAL CREATION GROUP
  4. Launch of a joint research and development project between Nihon Parkerizing, Kobayashi Pharmaceutical and JAXA to develop antibacterial treatment technology for use within spacecraft

WORKS

FUNCTIONAL CREATION GROUP

Launch of a joint research and development project between Nihon Parkerizing, Kobayashi Pharmaceutical and JAXA to develop antibacterial treatment technology for use within spacecraft

On March 1, 2020, Nihon Parkerizing Co., Ltd. (Head Office: Chuo-ku, Tokyo, President: Kentaro Sato, hereinafter “Nihon Parkerizing”), together with Kobayashi Pharmaceutical Co., Ltd. (Head Office: Osaka, Osaka Pref., COO: Akihiro Kobayashi, hereinafter “Kobayashi Pharmaceutical”) and the Japan Aerospace Exploration Agency (Head Office: Chofu City, Tokyo, President: Hiroshi Yamakawa, hereinafter “JAXA”) launched a joint research and development project (hereinafter, the “joint research”) to develop antibacterial treatment technology for use within spacecraft with the objective of applying this technology to manned space activity, a field that is anticipated to expand in future. The joint research aims to facilitate a spacecraft onboard environment that is suitable for more hygienic long-term stays.